losartan and Aura
losartan has been researched along with Aura in 10 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 7.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
| "Valproic acid is a widely used anticonvulsant drug with a broad therapeutic spectrum." | 6.73 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. ( Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H, 2007) |
| " We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 3.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
| "Valproic acid is a widely used anticonvulsant drug with a broad therapeutic spectrum." | 2.73 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. ( Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H, 2007) |
| " Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing." | 2.66 | Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020) |
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Slomski, A | 2 |
| Klein, P | 1 |
| Friedman, A | 2 |
| Hameed, MQ | 1 |
| Kaminski, RM | 1 |
| Bar-Klein, G | 2 |
| Klitgaard, H | 1 |
| Koepp, M | 1 |
| Jozwiak, S | 1 |
| Prince, DA | 1 |
| Rotenberg, A | 1 |
| Twyman, R | 1 |
| Vezzani, A | 1 |
| Wong, M | 1 |
| Löscher, W | 1 |
| Atanasova, D | 1 |
| Tchekalarova, J | 1 |
| Ivanova, N | 1 |
| Nenchovska, Z | 1 |
| Pavlova, E | 1 |
| Atanassova, N | 1 |
| Lazarov, N | 1 |
| Nozaki, T | 1 |
| Ura, H | 1 |
| Takumi, I | 1 |
| Kobayashi, S | 1 |
| Maru, E | 1 |
| Morita, A | 1 |
| Palestro, PH | 1 |
| Enrique, N | 1 |
| Goicoechea, S | 1 |
| Villalba, ML | 1 |
| Sabatier, LL | 1 |
| Martin, P | 1 |
| Milesi, V | 1 |
| Bruno Blanch, LE | 1 |
| Gavernet, L | 1 |
| Hong, S | 1 |
| JianCheng, H | 1 |
| JiaWen, W | 1 |
| ShuQin, Z | 1 |
| GuiLian, Z | 1 |
| HaiQin, W | 1 |
| Ru, Z | 1 |
| Zhen, G | 1 |
| HongWei, R | 1 |
| Cacheaux, LP | 1 |
| Kamintsky, L | 1 |
| Prager, O | 1 |
| Weissberg, I | 1 |
| Schoknecht, K | 1 |
| Cheng, P | 1 |
| Kim, SY | 1 |
| Wood, L | 1 |
| Heinemann, U | 1 |
| Kaufer, D | 1 |
| Pereira, MG | 1 |
| Becari, C | 1 |
| Oliveira, JA | 1 |
| Salgado, MC | 1 |
| Garcia-Cairasco, N | 1 |
| Costa-Neto, CM | 1 |
| Ueno, Y | 1 |
| Takagi, A | 1 |
| Kawana, M | 1 |
| Kasanuki, H | 1 |
| Gunes, A | 1 |
| Bilir, E | 1 |
| Zengil, H | 1 |
| Babaoglu, MO | 1 |
| Bozkurt, A | 1 |
| Yasar, U | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
1 review available for losartan and Aura
| Article | Year |
|---|---|
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef | 2020 |
Trials
1 trial available for losartan and Aura
| Article | Year |
|---|---|
Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liq | 2007 |
Other Studies
8 other studies available for losartan and Aura
| Article | Year |
|---|---|
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan suppresses the kainate-induced changes of angiotensin AT
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Pressure; Como | 2018 |
The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis.
Topics: Amygdala; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain Injuries; Cerebral | 2018 |
Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Ciprofloxacin; Da | 2018 |
Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain; Disease Models, Animal; Epilepsy; Losartan; Male; N | 2019 |
Losartan prevents acquired epilepsy via TGF-β signaling suppression.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Benzamides; Blood-Brain Barrier; Cells, Cult | 2014 |
Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticonv | 2010 |
Pulmonary hypertension during epileptic seizure with evidence of increased angiotensin II in pulmonary artery.
Topics: Aged; Angiotensin II; Anticonvulsants; Catheterization, Swan-Ganz; Drug Therapy, Combination; Epilep | 2005 |